RxDoctor Payments Data

Ruth Dupont, MD

Family Medicine · Naples, FLNPI 1710152376

Payments from drug & device makers

$7,267in general payments, 2019–2025

Across 405 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$820
  • Pfizer$780
  • Boehringer Ingelheim$695
  • Amgen$587
  • Merck$404
  • GSK$368
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,12898%
  • Education$1392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,267 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$154,321
Medicare patients
286
Services billed
2,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$93,295
EliquisApixaban26$27,653
JanuviaSitagliptin Phosphate22$25,355
Repatha SureclickEvolocumab14$14,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,735
MounjaroTirzepatide11$11,463
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$11,313
SynthroidLevothyroxine Sodium73$6,479
Levothyroxine Sodium364$3,880
Rosuvastatin Calcium119$3,531
Armour ThyroidThyroid,pork22$2,496
Np ThyroidThyroid,pork23$2,427
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,232
ValacyclovirValacyclovir Hcl44$2,064
Estradiol60$2,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$820$93,29565 claims
PfizerEliquis$780$27,65326 claims
MerckJanuvia$404$25,35522 claims
GSKTrelegy Ellipta, Anoro Ellipta$368$25,04840 claims
Lilly USA, LLCMounjaro$279$11,46311 claims
AbbVieSynthroid, Armour Thyroid$197$8,97595 claims
Acella Pharmaceuticals, LLCNp Thyroid$14$2,42723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →